We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nutrient Agar Substituted for Blood in Antibiograms

By LabMedica International staff writers
Posted on 17 Sep 2012
In laboratories in the developed world, blood agar plates are used to test antibiotic sensitivity of bacteria, but in resource poor laboratories, this may not be feasible.

Beta-hemolytic Streptococcus species also grow on Standard Nutrient Agar 1 (StNA1 and it has been suggested this type of nutrient medium could be used for running agar diffusion tests.

Bacteriologists at Globolab eV Laboratory (Assling, Germany) conducted 103 comparative tests to evaluate the growth characteristics of beta-hemolytic Streptococcus spp. More...
on StNA1 compared to Müller–Hinton agar supplemented with 5% sheep blood (B-MH). The specimens were obtained from patients admitted to a cooperating hospital in Germany and 16 beta-hemolytic streptococci strains were obtained.

Bacteria to be tested are streaked uniformly across a culture plate. Paper disks impregnated with eight different antibiotics (Oxoid; Wesel, Germany) to be tested are placed on the surface of the gelatinous agar. During incubation of the agar plate, the antibiotics diffuse from the disks into the surrounding agar. An effective agent will inhibit bacterial growth, and the size of such a zone of inhibition (ZoI) around the disk is measured. The relative effectiveness of a compound is determined by comparing the diameter of the ZoI with values in standard tables.

The authors found that found in 99 out of 103 (96.12%) of all cases that the absolute values of ZoI differences were smaller than or equal to 3 mm, and 92 out of 103 (89.32%) were smaller than or equal to 2 mm. The Standard Nutrient Agar 1 (StNA1) is marketed by Carl Roth GmbH (Karlsruhe, Germany) can be used for culturing Enterobacteriaceae, Pseudomonas spp., Staphylococcus spp., and Streptococcus spp. The B-MH used in the study was obtained from bioMérieux (Marcy l'Etoile, France).

The authors concluded that although blood agar is always the better choice for several reasons, the reading of the ZoI is often easier on StNA1 than on B-MH. This is because StNA1 is more transparent and, therefore, the edges between bacterial growth and the inhibition zone can be discerned more easily. In such places where no blood agar is available for conducting antibiograms, StNA1 is an appropriate substitute for blood-supplemented Müller–Hinton agar. The study was published on August 29, 2012, in the European Journal of Clinical Microbiology & Infectious Diseases.

Related Links:

Globolab e.V. Laboratory
Oxoid
Carl Roth GmbH




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.